Elutia Inc. (ELUT)
NASDAQ: ELUT · Real-Time Price · USD
1.880
-0.130 (-6.47%)
At close: Sep 5, 2025, 4:00 PM
1.910
+0.030 (1.60%)
After-hours: Sep 5, 2025, 5:29 PM EDT
Elutia Revenue
Elutia had revenue of $6.26M in the quarter ending June 30, 2025, a decrease of -0.45%. This brings the company's revenue in the last twelve months to $23.68M, down -5.22% year-over-year. In the year 2024, Elutia had annual revenue of $24.38M, down -1.50%.
Revenue (ttm)
$23.68M
Revenue Growth
-5.22%
P/S Ratio
2.94
Revenue / Employee
$464,373
Employees
51
Market Cap
79.70M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 24.38M | -370.00K | -1.50% |
Dec 31, 2023 | 24.75M | 896.00K | 3.76% |
Dec 31, 2022 | 23.85M | -23.54M | -49.68% |
Dec 31, 2021 | 47.39M | 4.71M | 11.03% |
Dec 31, 2020 | 42.68M | -219.00K | -0.51% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ELUT News
- 2 days ago - Elutia Selected to Exhibit EluPro™ Antibiotic Eluting BioEnvelope at Vizient Innovative Technology Exchange - GlobeNewsWire
- 10 days ago - Elutia to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 22 days ago - Elutia Inc. (ELUT) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 23 days ago - Elutia Delivers Robust Growth on the Strength of EluPro™ Market Adoption - GlobeNewsWire
- 5 weeks ago - Elutia to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025 - GlobeNewsWire
- 5 weeks ago - Dr. Michelle LeRoux Williams Earns Washington Business Journal's Medical Device Innovator Award - GlobeNewsWire
- 2 months ago - New Evidence Supports the Value of Elutia's Antibiotic-Eluting Platform for Implantable Devices - GlobeNewsWire
- 2 months ago - Elutia Wins Dual Honors for Innovation and Product Launches at 2025 Medical Device Network Excellence Awards - GlobeNewsWire